Clinical Advances in Hematology and Oncology
| 短名 | Clin. Adv. Hematol. Oncol. |
| Journal Impact | 1.21 |
| 国际分区 | ONCOLOGY(Q4) |
| ISSN | 1543-0790 |
| h-index | 43 |
Clinical Advances in Hematology & Oncology (CAH&O) is a monthly peer-reviewed journal reaching more than 27,000 hematology and oncology clinicians. CAH&O provides editorial content encompassing a wide array of topics relevant and useful to the fields of oncology and hematology, both separately and together. Content is directed by the strong input of today’s top thought leaders in hematology & oncology, including feature-length review articles, monthly columns consisting of engaging interviews with experts on current issues in solid tumor oncology, hematologic malignancies, hematologic disorders, drug development, and clinical case studies with expert commentary. CAH&O also publishes industry-supported meeting highlights, clinical roundtable monographs, and clinical review supplements.
| 涉及主题 | 医学生物内科学遗传学肿瘤科病理免疫学化学癌症生物化学重症监护医学外科法学政治学梅德林 |
| 出版信息 | 出版商: Millennium Medical Publishing, Inc.，出版周期: ，期刊类型: journal |
| 基本数据 | 创刊年份: 2003，原创研究文献占比: 89.19%，自引率:0.00%， Gold OA占比: 0.00% |
期刊引文格式
这些示例是对学术期刊文章的引用，以及它们应该如何出现在您的参考文献中。
并非所有期刊都按卷和期组织其已发表的文章，因此这些字段是可选的。有些电子期刊不提供页面范围，而是列出文章标识符。在这种情况下，使用文章标识符而不是页面范围是安全的。
只有1位作者的期刊
有2位作者的期刊
有3位作者的期刊
有5位以上作者的期刊
书籍引用格式
以下是创作和编辑的书籍的参考文献的示例。
学位论文引用格式
网页引用格式
这些示例是对网页的引用，以及它们应该如何出现在您的参考文献中。
专利引用格式
最新文章
The use of ADAMTS13 assays in thrombotic microangiopathies.
2021-11-1
The evolving use of CAR T-cell therapy in follicular lymphoma.
2021-11-1
New data for sacituzumab govitecan-hziy in the treatment of metastatic triple-negative breast cancer.
2021-11-1
Total neoadjuvant therapy approach in rectal adenocarcinoma.
2021-11-1
Lessons learned from the CAPTIVATE trial of ibrutinib plus venetoclax in CLL.
2021-10-1
Neoadjuvant and adjuvant approaches in surgically resectable NSCLC.
2021-10-1
Immunotherapy in esophagogastric cancer.
2021-10-1
Immunotherapy for small cell lung cancer: established applications and novel approaches.
2021-10-1
How quality of life can help guide selection of androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer.
2021-10-1
How to Choose Second-Line Treatment for Hepatocellular Carcinoma.
2021-9-1
Bleeding complications with Bruton tyrosine kinase inhibitors.
2021-9-1
IDH inhibitors in acute myeloid leukemia and myelodysplastic syndrome.
2021-9-1
The use of neoadjuvant therapy to further personalize breast cancer treatment.
2021-9-1
Alternatives to intensive treatment in patients with AML.
2021-8-1
PSMA-targeted radiotherapy in metastatic castration-resistant prostate cancer.
2021-8-1
New targets in endocrine-resistant hormone receptor-positive breast cancer.
2021-8-1
Current and future uses of digital pathology in oncology.
2021-8-1
HIPEC in ovarian cancer: hip or hype?
2021-8-1
Thrombosis with thrombocytopenia syndrome after COVID-19 vaccination
2021-7-1
Mechanisms of resistance to BTK inhibitors in patients with chronic lymphocytic leukemia.
2021-7-1
Diagnosis and management of neutrophilic myeloid neoplasms.
2021-7-1
The optimal duration of endocrine therapy in hormone receptor-positive breast cancer.
2021-6-1
Are novel agents ready to assume the mantle in the frontline treatment of mantle cell lymphoma
2021-6-1
Sentinel lymph node biopsy and completion lymph node dissection in melanoma.
2021-6-1
Incorporating palliative care into oncology practice: why and how.
2021-6-1
FLT3 inhibitors in acute myeloid leukemia: increasing options.
2021-6-1
How I manage chronic lymphocytic leukemia.
2021-6-1
The use of telemedicine in hematology and oncology
2021-5-1
The evolving role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer.
2021-5-1
Lenalidomide in dlbcl: Are we past the cell of origin?
2021-5-1
Recently approved drugs herald a new era in therapy for diffuse large B-cell lymphoma.
2021-5-1
Chimeric antigen receptor T-cell therapy plus checkpoint blockade in thoracic cancers.
2021-5-1
Asciminib for the treatment of patients with chronic myeloid leukemia
2021-4-1
Should venetoclax be used with or without anti-CD20 therapy for CLL?
2021-4-1
Determining the optimal duration of adjuvant therapy in colon cancer.
2021-4-1
New approaches to targeting the androgen receptor pathway in prostate cancer.
2021-4-1
Local and regional therapy for primary and locally recurrent melanoma.
2021-4-1
Update on antibody-drug conjugates in breast cancer.
2021-3-1
The evolving use of gemtuzumab ozogamicin in acute myeloid leukemia
2021-3-1
Highlights in leukemia and lymphoma from the 62nd American Society of Hematology Annual Meeting and Exposition: commentary.
2021-3-1
Circulating tumor DNA in early-stage breast cancer: new directions and potential clinical applications.
2021-3-1
Highlights in COVID-19 from the 62nd American Society of Hematology Annual Meeting
2021-3-1
New treatments for patients with progressive metastatic urothelial carcinoma.
2021-3-1
Highlights in CAR T-cell therapy from the 62nd American Society of Hematology Annual Meeting and Exposition: commentary.
2021-3-1
The FDA's patient-focused drug development initiative.
2021-2-1
When in the treatment continuum to use PARP inhibition in ovarian cancer.
2021-2-1
Contemporary management of advanced prostate cancer: an evolving landscape.
2021-2-1
PSMA-targeted therapy in prostate cancer.
2021-2-1
Highlights in chronic graft-vs-host disease from the 62nd American Society of Hematology Annual Meeting and Exposition: commentary.
2021-2-1
Early intervention in asymptomatic chronic lymphocytic leukemia
2021-2-1
帮你贴心管理全部的文献
研飞ivySCI，高效的论文管理
投稿经验分享
分享我的经验，帮你走得更远